Orion Diagnostica Oy, a subsidiary of Orion Corporation focusing on diagnostic tests, has received a notice of termination from its landlord to terminate the lease agreement of Orion Diagnostica's premises in Oulu. For this reason, the operations of Orion Diagnostica Oy in the current premises will end by the end of September 2017 at the latest.
Orion Diagnostica Oy has today given a negotiation proposal, as laid down in the Finnish Act on Co-operation within Undertakings, on reorganising operations and possible personnel reductions in Oulu. The negotiations concern 14 employees.
Possible reorganisation of the operations may lead to transfers of employees in Oulu, transfers of employees to other locations or to other positions in the Orion Group, changes to the terms of employment as well as possible terminations of employments. Should redundancies occur, the employer would, according to a preliminary estimate, give notices during 2017.
Kaisa Tarkkanen, President, Orion Diagnostica Oy
tel. +358 10 426 3268
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.